Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply

Affiliations

• ¹ Clinical Development, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA.
• ² BioPharmaceuticals Medical, AstraZeneca, Gothenburg SE431 83, Sweden.
• ³ BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
• ⁴ Patient Safety, Chief Medical Office, Research and Development, AstraZeneca, Gaithersburg, MD, USA.
• ⁵ Patient Safety, Chief Medical Office, Research and Development, AstraZeneca, Gothenburg SE431 83, Sweden. Electronic address: magnus.nord@astrazeneca.com.